ANDREW GORDON SWICK, Ph.D. University of North Carolina Nutrition Research Institute Kannapolis, NC 28081 704-250-5015 [email protected] EDUCATION and TRAINING Certificate in Plant-Based Nutrition 2010 Cornell University online Ph.D. Nutritional Sciences 1987 University of Wisconsin-Madison M.S. Nutrition, 1982 University of Nebraska-Lincoln B.S. Animal Science 1981 University of Florida-Gainesville Ph.D. Disseration: Activation of Brown Adipose Tissue Mitochodrial GDP Binding Sites. 201 pages; AAT 8716545. M.S. Thesis: Effects of Wheat Bran Fiber on Serum Lipids of Subjects Fed Omnivore, Lacto-Ovo and Vegetarian Diets. Fellowships: Postdoctoral Fellow 1990-1992 Johns Hopkins University Medical Center Postdoctoral Fellow 1987-1990 University of North Carolina-Chapel Hill PROFESSIONAL EXPERIENCE Associate Professor 2010- present Department of Nutrition in the Schools of Public Health and Medicine at the University of North Carolina at Chapel Hill and the Nutrition Research Institute at the North Carolina Research Campus in Kannapolis, North Carolina. Director of Obesity and Eating Disorders Research 2010- present University of North Carolina at Chapel Hill-Nutrition Research Institute at the North Carolina Research Campus in Kannapolis, North Carolina. Senior Consultant 2009-present CSO and Senior Consultant at Illuminate BioPharma Consulting LLC. Provide expert advice to Biotechnology, Pharmaceutical and Venture Capital companies and non-profit organizations on drug discovery research and development in addition to obesity, nutrition and metabolic diseases. Senior Director 2006-2009 Obesity and Atherosclerosis Translational Pharmacology in the Department of Cardiovascular and Metabolic and Endocrine Diseases (CVMED) at Pfizer Global Research and Development in Groton, Connecticut. Responsibilities included portfolio strategy and scientific leadership with respect to the identification and validation of therapeutic targets through nomination of compounds for development, target-specific and general biomarkers and translational pharmacology. Andrew Gordon Swick Directed efforts of the Obesity and Atherosclerosis teams (~50 Biologists). Integral member and sole research representative on the Development Team for Obesity that is responsible for strategy and planning up to Phase 3. Responsibility for official documents (i.e. INDs (investigational new drugs), IBs (investigator brochures), etc…) Chair of the Groton Research Recruiting Committee for biology and chemistry. Led effort to “reinvent” drug discovery including the identification and establishment of integrated CVMED research collaborations with academic institutions. Co-chaired, with a commercial and development lead, a working group that produced the 10 year obesity strategy .spanning research, development and commercial. Direct responsibility for scientific and strategic recommendations with respect to target pursuit and plans as a member of the CVMED Portfolio Team responsible for Licensing Review /Due Diligence for diabetes and obesity. Integral member of the CVMED Leadership Team and Research Management Forum responsible for setting and leading research strategy. Led the effort to externalize Pfizer obesity assets to venture capital, biotech and/or pharmaceutical companies. Director 2003-2006 Obesity Biology in the Department of Cardiovascular and Metabolic and Endocrine Diseases (CVMED) at Pfizer Global Research and Development in Groton, Connecticut. Key global representative on the Development Team that successfully moved multiple compounds to Phases 1, 2 and 3 and was responsible for up to 8 compounds at one point. Successfully initiated and led the effort to discover and develop Pfizer‟s first novel protein therapeutic for the treatment of metabolic diseases. Led and crafted the scientific rationale for several unique combination therapies that underwrote the development plans for first in human through Phase 2 studies. Integral role in establishing a new Pfizer obesity research team in Sandwich England and establishing a global metabolic diseases portfolio. Global research lead for a cross-Discovery, Development and Commercial team responsible for defining product concepts for obesity and obesity comorbidities. Manager 2001-2003 Obesity Biology in the Department of Cardiovascular and Metabolic Diseases at Pfizer Global Research and Development in Groton, Connecticut Led the nomination of multiple development compounds for obesity/diabetes including 5 in one year. Initiated and co-chaired a combination therapy team that established a strategy and framework for making decisions on how and when to combine 2 Andrew Gordon Swick compounds/drugs for the treatment of diabetes and obesity across research through to marketing. Chaired a matrixed Early Clinical Development Team for obesity that moved a compound, previously discovered through the efforts of my lab, through Phase 1 clinical studies. Project Leader 1998-2001 Diabetes and Obesity group of the Department of Cardiovascular and Metabolic Diseases at Pfizer Central Research in Groton, Connecticut. Integral role in justifying, building and leading the formation of an independent obesity research team at Pfizer. Reviewed and made recommendations on multiple potential licensing opportunities Key member of early clinical development team Senior Research Investigator 1997-1998 Diabetes and Obesity group of the Department of Cardiovascular and Metabolic Diseases at Pfizer Central Research in Groton, Connecticut. Led 2 independent Discovery research teams Established external collaborations to aid discovery efforts Senior Research Scientist 1992-1997 Diabetes and Obesity group of the Department of Cardiovascular and Metabolic Diseases at Pfizer Central Research in Groton, Connecticut. Initiated and successfully led a novel nuclear receptor program for the treatment of metabolic diseases Developed novel in vitro and in vivo models to guide decision-making Identified and nominated several development compounds Postdoctoral Fellow l990-1992 In the laboratory of M. Daniel Lane, Ph.D., in the Department of Biological Chemistry at the Johns Hopkins University School of Medicine. NIH Postdoctoral trainee 1987-1990 In the laboratory of Jane C. Azizkhan, Ph.D., at the Lineberger Cancer Research Center of the University of North Carolina at Chapel Hill. Research and Teaching Assistant 1983-1987 Research Assistant at the University of Wisconsin at Madison under the direction of Robert W. Swick, Ph.D. (no kinship). (1984-1985) Teaching Assistant under the direction of Robert D. Steele, Ph.D. Research Assistant 1982-1983 Vanderbilt University in the Department of Biochemistry under the direction of Conrad Wagner, Ph.D. 3 Andrew Gordon Swick Research Assistant 1981-1982 University of Nebraska at Lincoln under the direction of Constance Kies, Ph.D. Laboratory Assistant 1980-1981 University of Florida at Gainesville in the Department of Endocrinology and Metabolism under the direction of Robert Misbin, M.D. HONORS Early Clinical Management Team of the Year, Pfizer Global Research and Development 2007 da Vinci Award for Innovation, Pfizer Global Research and Development 2006 Therapeutic Strategy Award, Pfizer Global Research and Development 2004 MEMBERSHIPS 1987 Sigma Xi 1992 American Society for Biochemistry and Molecular Biology 2000 American Society for Nutritional Sciences 2008 New York Academy of Sciences Diabetes and Obesity Steering Committee 2011 UNC Nutrition and Obesity Research Center (NORC) member 2011 New York Academy of Sciences Overnutrition Steering Committee PUBLICATIONS Refereed Journal Articles: 1. Ralph P. Robinson , Jeremy A. Bartlett, Peter Bertinato, Andrew J. Bessire, Judith Cosgrove, Patrick M. Foley, Tara B. Manion, Martha L. Minich, Brenda Ramos, Matthew R. Reese, Theodore J. Schmahai, Andrew G. Swick , David A. Tess, Alfin Vaz, Angela Wolford. (2011) Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide. Bioorg. and Med. Chem. Let. 21:4150-4154. 2. C.M. Boustany-Kari, M.V. Jackson, C.P. Gibbons, A.G. Swick (2011) Leptin potentiates the anti-obesity effects of rimonabant. European Journal of Pharmacology, Volume 658, Issues 2-3, 11: 270-276 3. Richard L. Elliott, Kimberly O. Cameron*, Janice E. Chin, Jeremy A. Bartlett, Elena E. Beretta, Yue Chen, Paul Da Silva Jardine, Jeffrey S. Dubins, Melissa L. Gillaspy, Diane M. Hargrove, Amit S. Kalgutkar, Janet A. LaFlamme, Mary E. Lame, Kelly A. Martin, Tristan S. Maurer, Nancy A. Nardone, Robert M. Oliver, Dennis O. Scott, Dexue Sun, Andrew G. Swick, Catherine E. Trebino, Yingxin Zhang, (2010) Discovery of N-Benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1- phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N- isopropylacetamide, an Orally Active, Gut-Selective CCK1 Receptor Agonist for the Potential Treatment of Obesity. Bioorg. and Med. Chem. Let. 20:6797- 6801. 4 Andrew Gordon Swick 4. R. Wang and A.G. Swick (2009) Identification and characterization of a leptin- responsive human cell line. Biochem. Biophys. Res. Comm. 379 (4):835-839. 5. J.A Siuciak, D. Chapin, S.A. McCarthy, V. Guanowsky, J. Brown, P. Chiang, R. Marala, T. Patterson, P.A. Seymour, A.G. Swick and P. Iredale (2007) CP- 809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology, vol. 52( 2):279-90. 6. J.J. Ramsey, J.W. Kemnitz, W. Newton. K. Hagopian, T.A. Patterson and A.G. Swick (2005) Food intake in